Effects of Tranexemic Acid Versus Norethisterone Acetate on Endometrial Vasculature .
Primary Purpose
Dysfunctional Uterine Bleeding
Status
Unknown status
Phase
Phase 3
Locations
Study Type
Interventional
Intervention
norethisterone acetate
tranexamic acid tablets
Sponsored by
About this trial
This is an interventional treatment trial for Dysfunctional Uterine Bleeding
Eligibility Criteria
Inclusion Criteria:
- Age: 35-49 years old.
- Normal gynecologic and breast examination
- Women who have sterilization or husband is sterilized or accepts to use a suitable barrier contraception during the duration of the study.
- Heavy periods (were assessed by validated pictorial blood chart)
- Normal ultrasound, hysteroscopy and endometrial biopsy.
- Normal coagulation profile and thyroid function.
- No contraindication to tranexamic acid or Norethisterone acetate : allergy,History of arterial or venous thromboembolic disease,Disturbance of liver function or Severe renal impairment.
Exclusion Criteria:
- Women who are less than 35 years old or more than 49 years old.
- Women who had organic cause for heavy periods as uterine polypi,fibroids or endometriosis.
- Women taking hormonal preparation the month before starting the trial.
- Women with abnormal findings in pelvic ultrasound,hysteroscopy or endometrial biopsy.
- Women who suffer from uncontrolled diabetes or uncontrolled hypertension.
- Women with history of breast cancer or precancerous conditions.
Sites / Locations
Arms of the Study
Arm 1
Arm 2
Arm Type
Experimental
Experimental
Arm Label
norethisterone -women with Dysfunctional uterine bleeding
tranexemic acid-women with Dysfunctional uterine bleeding
Arm Description
Outcomes
Primary Outcome Measures
reducion of the menstrual flow.
Using Pictorial Blood loss assessment chart depends on counting the sanitary pads and scoring the amount of blood in them)
Secondary Outcome Measures
endometrial thickness in centimetre.
Measurement of the thickest part of the endometrium in centimetres in the longitudinal plan of the uterus using Two- Dimensional Transvaginal ultrasound
endometrial volume in cubic centimetre.
Measurement of the endometrial volume in cubic centimetres using Three-Dimensional transvaginal ultrasound
uterine artery Doppler indices.
Measurement of the uterine artery Doppler indices using Transvaginal ultrasound and taking the mean for both arteries.
endometrial three-dimensional vascular indices.
Measuring the vascularity in the endometrium using power doppler and Three -Dimensional transvaginal ultrasound.
Full Information
1. Study Identification
Unique Protocol Identification Number
NCT04290013
Brief Title
Effects of Tranexemic Acid Versus Norethisterone Acetate on Endometrial Vasculature .
Official Title
Effect of Tranexemic Acid and Norethisterone Acetate on Endometrial Vasculature in Women With Dysfunctional Uterine Bleeding.
Study Type
Interventional
2. Study Status
Record Verification Date
March 2020
Overall Recruitment Status
Unknown status
Study Start Date
April 22, 2020 (Anticipated)
Primary Completion Date
October 1, 2020 (Anticipated)
Study Completion Date
December 31, 2020 (Anticipated)
3. Sponsor/Collaborators
Responsible Party, by Official Title
Principal Investigator
Name of the Sponsor
Cairo University
4. Oversight
Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
Data Monitoring Committee
No
5. Study Description
Brief Summary
Heavy periods is a significant problem in reproductive age .It affects about a third of women in the childbearing period
Any of the following is considered to be heavy menstrual bleeding (Bleeding that lasts more than 7 days,Bleeding that soaks through one or more tampons or pads every hour for several hours in a row.Needing to wear more than one pad at a time to control menstrual flow.,Needing to change pads or tampons during the night or Menstrual flow with blood clots that are as big as a quarter or larger) .
Heavy periods can be caused by organic cause as fibroids, adenomyosis, polyps or they can be dysfunctional.Dysfunctional uterine bleeding is irregular uterine bleeding that occurs in the absence of recognisable pelvic pathology, general medical disease, or pregnancy. It reflects a disruption in the normal cyclic pattern of ovulatory hormonal stimulation to the endometrial lining.
Several treatment options include: hormonal treatment as norethisterone acetate,oral contraceptive pills, gonadotrophin releasing hormone analogue. ,tranexamic acid or non steroidal anti-inflammatory drugs.
The investigators plan to do a comparative study between norethisterone acetate and tranexamic acid regarding their control of the heavy periods as well as their effect on the uterine and endometrial vasculature.
Detailed Description
This is a Randomised controlled trial.The investigators will randomise 120 women who suffer from heavy periods (age range 35-49 years old) without organic cause (Dysfunctional bleeding ) into 2 groups, group A (60 women) : They will take norethisterone acetate 15 mg daily from day 5 to day 26 of the period for 3 months.
Group B (60 women): They will take 1 gm tranexemic acid three times daily from the start of menstrual period up to 5 days.The dose might be increased per day (Not more than 4 gm per day).
The investigators will check endometrial thickness, endometrial volume, uterine artery Doppler indices as well as endometrial and subendometrial indices before starting the treatment and 3 months afterwards.
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Dysfunctional Uterine Bleeding
7. Study Design
Primary Purpose
Treatment
Study Phase
Phase 3
Interventional Study Model
Parallel Assignment
Masking
ParticipantInvestigatorOutcomes Assessor
Allocation
Randomized
Enrollment
120 (Anticipated)
8. Arms, Groups, and Interventions
Arm Title
norethisterone -women with Dysfunctional uterine bleeding
Arm Type
Experimental
Arm Title
tranexemic acid-women with Dysfunctional uterine bleeding
Arm Type
Experimental
Intervention Type
Drug
Intervention Name(s)
norethisterone acetate
Intervention Description
norethisterone acetate 15 mg daily from day 5 of the cycle to day 26.
Intervention Type
Drug
Intervention Name(s)
tranexamic acid tablets
Intervention Description
tranexemic acid 1 gm three times daily from the first day of the menstrual cycle up to 5 days .The dose can be increased but not exceeding 4 gm per day.
Primary Outcome Measure Information:
Title
reducion of the menstrual flow.
Description
Using Pictorial Blood loss assessment chart depends on counting the sanitary pads and scoring the amount of blood in them)
Time Frame
3 months
Secondary Outcome Measure Information:
Title
endometrial thickness in centimetre.
Description
Measurement of the thickest part of the endometrium in centimetres in the longitudinal plan of the uterus using Two- Dimensional Transvaginal ultrasound
Time Frame
Before the intervention and 3 months afterwards
Title
endometrial volume in cubic centimetre.
Description
Measurement of the endometrial volume in cubic centimetres using Three-Dimensional transvaginal ultrasound
Time Frame
Before the intervention and 3 months afterwards
Title
uterine artery Doppler indices.
Description
Measurement of the uterine artery Doppler indices using Transvaginal ultrasound and taking the mean for both arteries.
Time Frame
Before the intervention and 3 months afterwards
Title
endometrial three-dimensional vascular indices.
Description
Measuring the vascularity in the endometrium using power doppler and Three -Dimensional transvaginal ultrasound.
Time Frame
Before the intervention and 3 months afterwards
10. Eligibility
Sex
Female
Gender Based
Yes
Minimum Age & Unit of Time
35 Years
Maximum Age & Unit of Time
49 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria:
Age: 35-49 years old.
Normal gynecologic and breast examination
Women who have sterilization or husband is sterilized or accepts to use a suitable barrier contraception during the duration of the study.
Heavy periods (were assessed by validated pictorial blood chart)
Normal ultrasound, hysteroscopy and endometrial biopsy.
Normal coagulation profile and thyroid function.
No contraindication to tranexamic acid or Norethisterone acetate : allergy,History of arterial or venous thromboembolic disease,Disturbance of liver function or Severe renal impairment.
Exclusion Criteria:
Women who are less than 35 years old or more than 49 years old.
Women who had organic cause for heavy periods as uterine polypi,fibroids or endometriosis.
Women taking hormonal preparation the month before starting the trial.
Women with abnormal findings in pelvic ultrasound,hysteroscopy or endometrial biopsy.
Women who suffer from uncontrolled diabetes or uncontrolled hypertension.
Women with history of breast cancer or precancerous conditions.
Central Contact Person:
First Name & Middle Initial & Last Name or Official Title & Degree
Eman Elkattan, MD,MRCOG,DFSRH
Phone
01212529213
Email
emyelkattan@gmail.com
First Name & Middle Initial & Last Name or Official Title & Degree
Yasser Khamis, MD
Phone
01125527555
12. IPD Sharing Statement
Plan to Share IPD
Undecided
Learn more about this trial
Effects of Tranexemic Acid Versus Norethisterone Acetate on Endometrial Vasculature .
We'll reach out to this number within 24 hrs